|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 729.05 USD | -1.73% |
|
-8.43% | -5.50% |
| 07:26pm | Where the Money's Moving |  |
| 06:45pm | Bayer's Eylea Secures EU Approval for Retinal Vein Occlusion | MT |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 26 | |||||||
| 26 | |||||||
| 18 | |||||||
| 16 | |||||||
| 29 | |||||||
| 21 | |||||||
| 25 | |||||||
| 5 | |||||||
| 20 | |||||||
| 19 | |||||||
| - | - | ||||||
| 11 | |||||||
| 11 | |||||||
| 23 | |||||||
| 20 | |||||||
| 11 | |||||||
| - | 1 | ||||||
| 10 | |||||||
| 12 | |||||||
| Average | 17 | |||||||
| Weighted average by Cap. | 20 |
- Stock Market
- Equities
- REGN Stock
- Sector Regeneron Pharmaceuticals, Inc.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition